SCHEMBL23934269

SCHEMBL23934269

COc1ccc(C(=O)Nc2cc(NC(=O)c3ccc(OC)c(OC)c3)c3c(c2)C(=O)NC3=O)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
MAPT P10636 1/20 0.55
PDE4D Q08499 1/20 0.53
KMT2A Q03164 6/20 0.52
MEN1 O00255 4/20 0.52
ALDH1A1 P00352 4/20 0.52
PKM P14618 1/20 0.52
KDM4E B2RXH2 2/20 0.51
CYP1A2 P05177 2/20 0.49
HPGD P15428 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
MAPK14 Q16539 2/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
CHEK1 O14757 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934212 0.87 KMT2A (0.50) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL23934203 0.87 POLB (0.54) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL23934278 0.83 MAPT (0.54) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL23934213 0.79 CASP3 (0.61) POLBMAPTKMT2AMEN1ALDH1A1
SCHEMBL6349892 0.73 ATM (0.68) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL11244161 0.72 PDE4D (0.81) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL13561145 0.72 KMT2A (0.70) POLBMAPTKMT2AMEN1ALDH1A1
SCHEMBL9339478 0.72 PKM (0.67) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL4141962 0.71 MEN1 (0.89) POLBMAPTPDE4DKMT2AMEN1
SCHEMBL6676301 0.71 MAPK14 (0.77) POLBMAPTPDE4DKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885MAPT 1837/4885PDE4D 3902/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885MAPT 1837/4885PDE4D 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.